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Interferons (IFNs) are proteins with a wide rangeofbiological effects. IFNs have antiviral and
antiproliferative properties. They modulate both the immune system and the expression of cell
phenotype. In the past decade, the IFNs have received intense clinical scrutiny. Alpha IFN is the
best studied anddisplays activity in manyneoplasticdiseases; it hasshown the most promise in the
hematological cancers although several solid tumors, including epidemic Kaposi's sarcoma, renal
cell carcinoma, and melanoma, respond. No neoplastic disease, however, has been cured by the
IFNs. IFN seems to be most active in the setting ofminimal residual disease, and clinical studies
evaluating its role in the adjuvant setting are under way. Other areas of research include trials
combining IFN with cytotoxicdrugsorother biological response modifiers, and maintenance IFN
to prolong remissions following successful induction therapy.
INTRODUCTION
Researchers recognized in 1957 that cultured cells exposed to heat-inactivated virus
produced a substance that conferred cellular resistance to subsequent lytic viral
infection [1]. This substance was named interferon (IFN) and was later shown to be a
group of related protein cytokines produced by many different cells in response to
viruses, ds RNA, and other agents. IFNs inhibit viral replication, modulate immune
function, and have a direct antiproliferative effect on tumor cells. They are classified
according to antigenic and physicochemical properties into three major types: alpha
(leukocyte), beta (fibroblast), and gamma (immune) IFNs [2]. Many subtypes of
alpha IFN have been characterized; these subtypes share a 75 percent homology in
amino acid sequence and show some differences in biological activity [3].
Only one protein species has been identified for beta IFN; this protein shares a 29
percent homology ofamino acid sequencewith alpha IFN [4]. Beta IFN wasoriginally
obtained from stimulated fibroblasts, but, like alpha IFN, it can be produced by
virtually any cell under the proper stimulus. Alpha and beta IFNs have been termed
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type I IFNs because of their stability at low pH [4]. These IFNs bind to the same cell
surface receptor [5].
Gamma IFN, produced by activated T lymphocytes, is labile in an acid environment
and is called a type II IFN. The degree of homology between alpha and gamma IFN
may be about 12 percent but is currently debated [6]. Gamma IFN has a cellular
receptor distinct from the type I IFNs [7].
The first clinical trials of IFN involved a partially purified polyclonal mixture of
alpha IFN produced by leukocytes obtained from banked transfusion blood [8]. In
terms of IFN protein, this preparation was about 0.5 percent pure, extremely
expensive, and available only in minute quantities. In 1975, Finter introduced a
method for obtaining large amounts of natural alpha IFN from stimulated lympho-
blastoid cells. This product contained many different subtypes of alpha IFN and has
been marketed as IFN-a-nl [9]. Production ofa single subtype of a IFN subsequently
became possible through recombinant DNA technology. Two recombinant products,
IFN-a-2a and IFN-a-2b have been marketed in the U.S.A. These IFNs differ in
composition by only one amino acid and probably represent allelicvariants ofthe same
subtype [10]. The U.S. FDA recently approved the useofthese two recombinant IFNs
for the treatment ofhairy cell leukemia (HCL) and Kaposi's sarcoma.
BIOLOGICAL ACTIVITY
Alpha IFN has numerous biologic effects which can be grouped into four major
categories: antiviral [11], antiproliferative [2,12], immunomodulatory [13-15], and
alteration of cell phenotype (including expression of tumor-associated antigens and
oncogenes) [16-18]. These effects are mediated via specific cell surface receptors. The
antiviral activity of IFN depends, at least in part, on the activation of endonuclease.
This enzyme inhibits protein synthesis by cleaving viral and host RNA [19-23]. Other
mechanisms proposed from cell culture data include impairment of 5'-methylation of
newly synthesized RNA, inhibition of phosphodiesterase, and inhibition of virus
maturation and budding [19,24].
The direct antiproliferative activity of IFN has been established both in cell culture
and in immunodeficient nude mice. The mechanism for this effect has not yet been
determined. Cell cycle changes prolonging each phase ofthe cell cycle and the overall
cell generation time have been described [3] and result in cytostatic and possibly
cytotoxic effects [25]. Some studies suggest that changes in cell cycle phases may
result from DNA polymerase inhibition, from a loss of coordination between DNA
replication and subsequent cell division [19], or from inhibition of the polyamine
synthesis pathway [26]. Alternatively, IFNs may affect proliferation and differentia-
tion via modification of oncogene expression. This modulation appears to play an
important role in the normalization ofcell growth and the disappearance ofmalignant
characteristics [16,17,27-31].
Alteration of immune function includes effects on monocyte, neutrophil, natural
killer (NK) activity, T-cell cytotoxicity, and B-cell immunoglobulin production.
Various studies have yielded conflicting results as to the type ofeffect IFN has on these
immune cells. The differences are due in part to a lack of standardization of assays
used to measure immune function. Great disparity exists in how immune cells are
collected, separated, stimulated, and cellular function measured [31]. Certain trends,
however, are apparent in most studies, and these effects are listed in Table 1. IFN
frequently inhibits immune cell function, and this effect may be related to its
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TABLE I
In Vivo Immunomodulatory Effects of Alpha IFN
Immune Component Effect Reference
B lymphocyte Decrease in immunoglobulin pro- [32,33]
duction
T lymphocyte Decreased proliferative response to [31,32]
mitogens and mixed lymphocyte
culture
Monocyte Increased Fc receptor-mediated [31]
phagocytosis
NK cell Short-term increase usually fol- [31-33]
lowed by a decline in activity [34,35]
Antibody-dependent cellular Variable effect [31,35]
cytotoxicity (ADCC)
MHC phenotype Increased expression ofclass I and [13]
II antigens
Oncogene expression Variable effect [16-18,27-31,40-42]
ADCC, antibody-dependent cellular cytotoxicity; MHC, major histocompatibility complex
antiproliferative activity. IFN produces a decline in total lymphocyte count and
suppresses immunoglobulin production [32,33]. NK cell activity falls within hours of
an injection of IFN and then rebounds to levels above baseline one to three days after
the first dose [34,35]. Repeated IFN administration, however, results in diminished
NK activity in many, but not all, patients [31-33,34,35]. Future studies must clarify
which immunological mechanisms are involved in the antitumor effect so that the dose
and administration schedule of IFN can be optimized. Since many cancer patients
have selective defects in immune function, it will also beofinterest todetermine ifIFN
can reverse these defects and if reversal produces a clinical response. In addition, it
must be determined why chronic IFN exposure frequently produces hyporesponsive
NK cells and whether secondary malignancies or other clinical sequelae result from
this chronic immunosuppression.
The primary mechanisms of IFN antitumor action may be multifactorial and
dependent on the tumor type [36]. In viral-associated tumors such as laryngeal
papillomatosis and condyloma acuminatum, the antiviral effect of IFN may be
involved [37]. Clonogenic assays and immunodeficient nude mice models support a
direct antiproliferative effect rather than immunomodulation [38,39]. Inhibition of
oncogene expression may be important in some malignancies such as HCL and chronic
myeloid leukemia (CML) [40-42].
Beta and gamma IFNs share most of the biological effects of the alpha IFNs [43].
One important difference, however, relates to the expression of antigens of the major
histocompatibility complex (MHC). Although all the IFNs increase expression of
MHC antigens, gamma IFN is significantly more potent than the other IFNs in
modulating the class II antigens [13]. Other important immunomodulatory effects of
gamma IFN include stimulation ofmonocyte function [3] and promotion ofmicrobici-
dal killing via superoxide generation [44].
DISTRIBUTION AND TOXICITY
IFNs are small protein molecules with molecular weights ranging from approxi-
mately 20,000 daltons for alpha and beta IFN to about 70,000 daltons for gamma
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IFN. The pharmacokinetics of recombinant and natural alpha IFN are comparable
[45-47]. Alpha IFN passes freely between the blood and extravascular pools.
Cerebrospinal fluid (CSF) penetration is poor, with serum-to-CSF ratio varying from
67:1 to 1,100:1 [48-51]. Animal studies indicate that alpha IFNs are rapidly filtered
by the glomeruli and catabolized in the renal tubules. Although alpha IFN is
non-dialyzable, low-dose therapy in hemodialysis patients has not led to drug accumu-
lation [52-54].
Intravenous administration of all three classes of IFN results in high peak
concentrations followed by a rapid decline from the serum. Lower peak serum
concentrations and longer serum half-lives can be obtained by using the intramuscular
or subcutaneous routes. Using equivalent doses, intramuscular injection ofalpha IFN
results in peak serum levels that are only about 10 percent of the maximal levels
observed after intravenous administration [55].
Most side effects of IFN are dose-dependent, more conspicuous in the elderly, and
are reversible when treatment is stopped [56-58]. At the dose range recommended for
HCL (3 x 106 U three times a week or less), side effects from IFN are usually mild.
Studies evaluating high-dose IFN, with daily doses greater than 20 x 106 U,
frequently result in severe toxicity requiring dose modification. Except for minor
quantitative differences, it appears that the toxicities of beta and gamma IFN are
similar to that of alpha IFN [59-63]. The most common adverse effect is an acute
influenza-like syndrome seen in more than 95 percent of the patients [56-58]. In
patients receiving IFN at least three times weekly, these symptoms usually decrease in
intensity and dissipate within seven to ten days of continued therapy. They can recur
though, iftherapy is interrupted [58].
The other side effects of IFN are subacute or chronic. Common neurological effects
include fatigue, weakness, anorexia, and an inability to concentrate. Large systemic
doses (>100,000 x 106 U daily) produce psychoses, confusion, seizures, and psycho-
motor retardation [64-66]. These effects have been the dose-limiting toxicities in the
majority ofclinical trials and do not tend to decrease with time [56-58].
Hematologic toxicity can be seen in all cell lines but is most pronounced in white
cells. Leukopenia occurs consistently within hours after administration. A decrease of
approximately 50 percent in the leukocyte count is frequently observed after the first
week oftreatment, but the count rapidly recovers once treatment is discontinued. This
result and bone marrow studiessuggest that IFN causes redistribution ofthe white cell
population rather than myelosuppression [56-58,671. Anemia due to IFN therapy is
dose-related. When it occurs, it is usually normochromic, normocytic, and may require
weeks to months for recovery [56-58]. Rare cases of Coombs' positive hemolytic
anemia have been reported [58,68]. Interferon-induced thrombocytopenia is rare in
patients with solid tumors but has been reported in 25-50 percent of patients with
chronic lymphocytic leukemia and multiple myeloma [58]. A few cases of immune-
mediated thrombocytopenia and coagulopathy induced by IFN have also been
described [69-71].
Cardiovascular toxicities, such as tachycardia and hypotension, are usually related
to the flu-like syndrome [58]. Effects on thegastrointestinal system (including nausea,
vomiting, and diarrhea) are generally mild and occur in approximately one-third of
patients. Elevation of hepatic transaminases is frequently seen but is rarely clinically
significant. The most common renal toxicity is mild proteinuria [56-58], although rare
cases of acute renal failure and nephrotic syndrome have been described [72,73]. The
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most prominent dermatologic reactions are mild alopecia and transient skin rashes.
The paradoxic profuse growth ofeyelashes has also been seen [74].
Other rare side effects include autoimmune thyroid disease (hyperthyroidism and
hypothyroidism), parotitis, epididymitis, pernicious anemia, and systemic lupus ery-
thematosus [75-79]. IFN has also been shown to depress the drug-metabolizing
hepatic cytochrome P-450 system and could potentially predispose to drug interactions
[80]. Although this effect has not been ofmajorclinical significance thus far, enhanced
phenobarbital toxicity was reported in one case [81]. With the incorporation of
interferon into multi-drug regimens, it will be important to remain vigilant for other
potential drug interactions.
Since alpha IFN currently represents primarily a palliative treatment modality,
special attention must be directed toward minimizing toxicity while not compromising
efficacy. Administration of IFN at bedtime, preceded by acetaminophen and a
benzodiazepine, improves patient tolerance by minimizing fever and chills and
allowing patients to "sleep through" other potential side effects which often occur
during the first week oftherapy.
IFN NEUTRALIZING ANTIBODIES
Both natural and recombinant human alpha and beta IFNs can be antigenic in man
[58]. The antigenic potential ofgamma IFN is currently being evaluated but appears
to be low. Factors affecting antibody (Ab) formation include the dose and schedule of
IFN and the type ofmalignancy. Peak Ab titers occur five days following cessation of
IFN therapy. Depending on the type of assay used, Abs are detectable in 2.5-25
percent of patients. Controversy exists as to the relative antigenicity of the two
approved recombinant IFN preparations. Differences determined in some studies may
simply reflect differences in the sensitivities of the Ab assay employed [57,82,83].
Some Abs induced by one recombinant IFN cross-react with the other recombinant
preparation. In vitro studies, however, show no cross-reactivity of recombinant IFN
Abs with partially purified natural IFN [24].
The clinical relevance of neutralizing antibodies remains unclear. Reports of
patients whose response was potentially shortened due to antibody formation, however,
are increasing in the literature [58,83-85]. Steis et al. [24] recently reported on 51
hairy cell leukemia patients treated with recombinant alpha IFN. Of the 16 patients
who developed neutralizing antibodies in this series, six also became clinically resistant
to IFN. This result suggests that in some cases clinical resistance to IFN may be
through the development of IFN-neutralizing antibodies. Other mechanisms for
resistance must also occur, however, since the presence of antibodies does not
necessarily signal the end ofa clinical response.
CLINICAL APPLICATIONS IN ONCOLOGY
Although alpha IFNs have been extensively used in the clinic, the experience with
the other IFNs has been restricted to a relatively few phase I and phase II trials. Thus
far, neither beta nor gamma IFN has shown more activity than alpha IFN. Figures 1
through 3 summarize the results reported for malignancies in which IFN has been
extensively evaluated. For solid tumors and lymphomas, responses are defined in the
standard fashion: a complete response (CR) indicates disappearance of all evaluable
tumor, and a partial response (PR) means more than a 50 percent reduction in
measurable disease. The response criteria for the hematologic malignancies is defined
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in the text. These figures should be interpreted with caution since they aggregate data
from many studies which used alpha IFN in different dosage schemas and had a
different patient mix.
EXPERIENCE IN HEMATOLOGIC MALIGNANCIES
Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder which is relatively
refractory to standard cytotoxic agents. Since the first promising report by Quesada et
al. [86] in 1984, a number of clinical trials have been published in the treatment of
HCL with alpha IFN [85-97]. In these trials, a CR has usually been defined as a
peripheral hematologic remission with 5 percent or less hairy cells in the marrow and a
PR as a peripheral hematologic remission with 50 percent or greater reduction in
leukemic infiltration of the marrow. Most clinical trials have used IFN doses in the
range of 3 x 106 U subcutaneously or intramuscularly three times a week for
approximately one year. Lower doses have been evaluated, and although they result in
less fatigue, they are probably less efficacious [98,99]. Extending treatment an
additional six months after a year of therapy has not improved the CR rate nor
prolonged the interval until disease progression [100]. The CR rate is low with IFN, as
illustrated in Fig. 1; however, 70-90 percent ofpatients experience marked symptom-
atic and hematologic improvement. Theredoes not appear to be a significant difference
in response between splenectomized and non-splenectomized patients. Hematologic
improvement is gradual, with normalization of the platelet count usually occurring
within two months, and normalization ofthe hemoglobin and granulocyte count within
four to six months. Following discontinuation of IFN, the percentage of hairy cells
increases gradually in the marrow, with 45 percent of the patients requiring retreat-
ment at a median of 25.4 months because of progressive cytopenias [100,101].
Remissions can be re-induced with alpha IFN in most patients [85,95,96,100]. In
contrast to alpha IFN, gamma IFN appears to be inactive in HCL, a result which
correlates with different intracellular effects on hairy cells by the two types of IFN
[102].
Recently, a cytotoxicdrug pentostatin (2'-deoxycoformycin) has been shown to have
marked activity in HCL. The drug is well tolerated and produces a CR in >80 percent
ofthe patients treated. It is too early to assess late sequelae or determine ifpentostatin
can cure hairy cell leukemia [103]. A multi-institutional trial comparing pentostatin to
alpha IFN is currently under way.
Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a hyperproliferative disorder ofmultipotential
stem cells. The Philadelphia chromosome (Ph'), present in 90 percent ofthesepatients,
represents a reciprocal translocation (t9,22) involving the proto-oncogene c-abl. Based
on in vitro data showing that alpha IFN can inhibit proliferation ofboth leukemic and
normal myeloid colony formation and downregulate oncogene expression [104],
Talpaz et al. [105,106] investigated the effect of human leukocyte IFN in controlling
myeloid proliferation in chronic myeloid leukemia (CML). They employed doses of
alpha IFN ranging from 3 to 9 x 106 Udaily until hematologic remission was obtained,
followed by slightly lower doses for remission maintenance. Complete remission was
defined as normalization of white cell and platelet count and disappearance of
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splenomegaly. Decrease in white cell count to at least 50 percent ofpretreatment level
and below 20,000/,uL was called a PR. Ofthe 51 patients treated, 71 percent achieved
a CR and 9 percent a PR. The median time to remission was 14 weeks (range, 2-55
weeks). Cytogenetic responses were also obtained. Twenty of the 36 responding
patients showed a reduction in the percentage of (Ph')-positive metaphases with five
patients having complete disappearance of all Ph'-positive cells on at least one
examination. Optimal response was achieved at a dose of 5 x 106 U/M2 daily in
lower-risk disease, which they defined as newly diagnosed, previously untreated,
Ph'-positive patients with low to moderately high leukocytosis. Similar therapeutic
results have been reported in four subsequent series. The cytogenetic changes in these
studies, however, were less impressive, apparently because IFN was given in lower
doses [104,107-109]. Unfortunately, toxicity is significant when IFN is given in the
optimal dose schedule of 5 x 106 U/m2/day. Nearly one-third of patients experience
grade 3 toxicities, consisting of cytopenias, hepatitis, and neurological symptoms.
Whether IFN offers long-term therapeutic gain over standard cytotoxic agents to
justify this toxicity is not known. Ongoing phase III trials are comparing IFN to
hydroxyurea. Alpha IFN is also effective in controlling thrombocytosis in CML and
other myeloproliferative disorders [110-113]. IFN activity during the accelerated and
blast phases of CML is minimal with only a minority of patients showing brief
improvement in the hematologic deterioration [106-109].
The efficacy of gamma IFN in CML is under evaluation and preliminary results
suggest that about 25 percent of patients achieve a complete hematologic remission.
Particularly interesting is laboratory work showing a potential synergy between alpha
and gamma IFN [114]. Clinical trials employing combinations of alpha and gamma
IFNs for CML are currently under way. Other investigators are looking at alpha IFN
combined with standard cytotoxic agents such as busulfan for the chronic phase ofthis
disease [1 15].
Lymphomas
Lymphomas are a heterogeneous group oflymphoreticular neoplasms which can be
divided into Hodgkin's disease, non-Hodgkin's lymphoma, and a miscellaneous group
which includes the cutaneous T-cell lymphomas. As shown in Fig. 1, the best results
have been observed in the cutaneous T-cell lymphomas with about 70 percent of
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patients responding to alpha IFN. Responses appear to be dose-related and last from
three months to more than three years [116-119]. Among the non-Hodgkin's group,
IFN is most effective for the low-grade lymphomas with follicular histologies
[120-127]. Efficacy might be further improved if IFN were combined with cytotoxic
drugs [128,129]. Only limited information is available in Hodgkin's disease and the
intermediate and high-grade lymphomas, but they do not appear to be very responsive
to alpha IFN [121,122].
Chronic Lymphocytic Leukemia andAcute Leukemias
Alpha IFN exhibits antitumor activity in about 20 percent of patients with chronic
lymphocytic leukemia (CLL) but remissions are usually partial and short-lived
[121,125,127,130-133]. Early-stage disease is most likely to respond but hematologic
improvement is not sustained once IFN is withdrawn [134]. IFN has also very limited
activity as induction therapy in the acute leukemias [135-139]. One randomized
study, however, suggests that alpha IFN administered after marrow transplantation
for acute lymphocytic leukemia may reduce the risk of leukemic relapse [140]. This
interesting finding warrants further evaluation.
Multiple Myeloma
Using a 50 percent or greater reduction in the myeloma immunoglobulin as response
criteria, about 20 percent of both untreated and refractory myeloma patients achieve
remissions with alpha IFN [111,117,141-149]. The median duration of response to
IFN ranges from two to more than 14 months, with approximately one-third of the
patients having remissions lasting more than one year [141-144]. Although the
activity of IFN as a single agent is modest in multiple myeloma (MM), recent studies
suggest that IFN may play a more important role when used sequentially or in
combination with cytotoxic agents. The Myeloma Group of Central Sweden recently
reported a randomized trial showing a higher response rate (82 percent vs. 52 percent,
p < 0.01) and a lower disease progression (4 percent vs. 21 percent) when alpha IFN
was combined with melphalan/prednisone than when this chemotherapy regimen was
used alone [150]. IFN may also be useful as maintenance therapy in this disease. In
patients who had responded to induction chemotherapy, preliminary results of a
multi-center trial have shown significantly longer remission durations in a group of
patients randomized to maintenance alpha IFN until relapse compared with control
[151]. It is not yet known whether prolongation of remission will translate into a
survival advantage.
EXPERIENCE IN SOLID TUMORS
In contrast to the hematologic malignancies, IFN activity in solid tumors is much
more modest (Fig. 2). The highest response rate has been observed in epidemic
Kaposi's sarcoma (EKS) [152-159]. Alpha IFN has recently received FDA approval
for treatment of EKS. Indications for treatment include pulmonary KS, rapidly
progressive cutaneous disease, or symptomatic visceral involvement. Higher doses of
IFN produce better response rates [157]. At the recommended doseof3 x 106 U daily,
alpha IFN produces tumor regression in 30-40 percent of treated patients. Factors
predictive of improved response include: the absence of a previous opportunistic
infection, lack of systemic symptoms (fever, sweats, weight loss), and relative
immunological competence as measured by the number of circulating CD4 lympho-
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cytes and intact skin testing for delayed hypersensitivity. In this subset ofpatients, the
overall response rate exceeds 50 percent [158,159]. Toxicity is significant, however,
with up to a third of patients requiring dose reduction because of asthenia or
neutropenia [156]. Equivalent response rates can be obtained with several cytotoxic
regimens, but some of these agents produce prolonged myelosuppression and the
development ofopportunistic infections has been observed. Combinations of IFN with
cytotoxic drugs are probably no more efficacious at the cost of increased side effects.
IFN's activity in this disease may be due in part to a direct anti-retroviral effect
[1a60,161, and current studies are evaluating the combination of IFN with AZT.
Phase I trials ofgamma IFN have failed to show significant antitumor effect. Based on
in vitro data, very low-dose gamma IFN alone, or in combination with othercytokines,
is currently being investigated [71859].
Of the solid tumors, renal cell carcinoma (RCC) and malignant melanoma have
been the most amply studied [1i62-181. While the overall response rate does not
exceed 20 percent in either melanoma (MEL) or renal cancer, alpha IFN is one ofthe
few standard agents with definite and reproducible antitumor activity in thesediseases.
An occasional patient will experience a sustained remission [164,167,180]. The role of
IFN as adjuvant therapy following resection of localized disease is currently being
studied in both ofthese malignancies.
Response rates of 20 percent to systemically administered IFN have also been
reported in brain tumors [117,182-186]. This estimate ofactivity is based, however, on
small series which included patients just completing treatment with radiation or
surgery, making assessment ofobjective responses difficult. Alpha IFN is a clinically
useful drug in malignant endocrine tumors. Although the objective response is low, 40
percent to 50 percent of patients treated experience subjective improvement in
endocrine-related symptoms and have more than a 50 percent reduction in the
biologically active peptides [78,187-190].
For ovarian, bladder, head and neck, and cervix cancers, systemic administration of
IFNs has largely proven ineffective [117,191-200]. Preliminary evidence, however,
suggests that IFN may be synergistic when used with cytotoxic drugs [201].
Locoregional or intralesional administration of IFN also appears promising, and
larger-scale studies will be needed to assess the merits of these modalities (Fig. 3).
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neal (IP) administration of IFN reaches peak concentrations up to 3 logs greater than
those obtainable in plasma. Locoregional therapy for ovarian cancer has been reported
in one series of 14 patients [202]. All had a positive second-look laparotomy following
combination chemotherapy and received IP IFN at the maximally tolerated dose of
50 x 106 U/M2 per week for 16 consecutive weeks. After completion of therapy, 11
patients were surgically restaged. Five responses were noted, with four patients
attaining a complete remission. These four patients all had non-bulky disease at the
start of the trial, suggesting that alpha IFN may be most effective in the setting of
minimal residual disease. Phase I trials evaluating IP beta and gamma IFN have also
been conducted. In one trial, four of seven patients with advanced refractory disease
showed a clinical response to beta IFN [203]. Results with IP gamma IFN have been
less promising [204].
Carcinoma of the bladder presents as superficial disease in 80 percent of patients.
Following transurethral resection, 50 percent of these patients will have a recurrence.
Patients with high-grade lesions, multiple recurrences, invasion ofthe submucosa, and
carcinoma in situ (CIS) are candidates for intravesicular therapy. Several agents
including cytotoxic drugs and bacillus Calmette-Guerin (BCG) have shown activity in
these settings. With these agents, responses in superficial transitional cell carcinoma
(TCC) and CIS have ranged from 20-60 percent. Following resection, the recurrence
rate of TCC is decreased from 45 percent to 15-20 percent if prophylactic BCG is
given [205]. Intravesicular alpha IFN is as effective as standard agents and is less toxic
[206]. The optimal dose and duration of therapy of intravesicular IFN is currently
under investigation.
In non-melanomatous skin cancers, intralesionally injected alpha IFN exhibits
marked antitumor activity. In one series ofeight patients with basal cell carcinoma, all
achieved a pathologic CR [207]. In 17 patients with squamous and basal cell
carcinoma, subsequent resection showed no residual disease in 13 [208]. IFN may be
an alternative tosurgery in thesediseases and in somecases provide a superior cosmetic
result.
Intra- or perilesional injections of IFNs have also been employed in some head and
neck cancers, in locally advanced carcinoma of the cervix, and in brain tumors. No
conclusions in regard to efficacy can be made because of the small numbers treated
[208-212]. Some activity, however, has been shown, and multi-center trials are under
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way. Unfortunately, IFNs have little or no activity in the more common solid tumors
such as breast [213-220], lung [221-225], colon [81,226-231], stomach [117,232],
and prostate cancer [233,234]. Osteosarcoma, soft tissue sarcomas, and hepatoma are
also usually refractory to IFN therapy [187,232,235].
SUMMARY
Intensive trials have defined the activity of alpha IFN and the maximal tolerated
dose. This information is still being accumulated for beta and gamma IFN. Despite
early optimism, the IFNs have not proven to be a panacea for cancer treatment. No
tumor has been rendered curablewith the IFNs, and the most common neoplasms have
sadly proved exceedingly resistant. The current clinical significance ofthe IFNs belies
their importance in oncology: IFNs represent the first class of cytokines isolated and
placed in clinical trials.
IFN's antitumor effect is reproducible in several hematologic malignancies but only
in a handful ofsolid tumors. IFN is a clear advance in the treatment ofHCL, but even
this indication is jeopardized by pentostatin. In myeloma, maintenance therapy with
IFN enhances the durability ofremission and may result in improved survival. For the
chronic phase of CML, IFN as a single agent or in combination with cytotoxic drugs
may prove to be superior to cytotoxic agents alone.
In responsive solid tumors, IFN seems to be most active in the setting of minimal
residual disease. Clinical trials are currently examining IFN as an adjuvant therapy
following surgical resection of high-risk melanoma and renal cell carcinoma. IFN is
also active as a local therapy in several malignancies, including superficial bladder
cancer and locally advanced ovarian carcinoma. It is too early to determine what role
IFN will have in the management ofthese diseases.
Comprehension ofthe role ofthe IFNs and other cytokines in the complex function
of the immune system remains in its infancy. Early data suggest that IFN used in
combination with other biologicals or cytotoxic drugs is more effective than when it is
used as monotherapy. As the physiological role of IFN and other cytokines is
eventually elucidated, more rational strategies to employ biological proteins in cancer
treatment will be designed.
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